Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Prognostic Value of the Gustave Roussy Immune Score in Patients with Locally Advanced Gastric Cancer Receiving Neoadjuvant FLOT Chemotherapy: A Retrospective Cohort Study.

Diagnostics (Basel, Switzerland)·2026
Same author

Prognostic Value of the Objective Prognostic Score and Palliative Prognostic Index for Short-Term Mortality in Terminal Cancer Patients Receiving Best Supportive Care: A Prospective Observational Single-Center Study.

Journal of clinical medicine·2026
Same author

Prognostic Value of Albumin-to-CEA Ratio in Metastatic Colorectal Cancer: A Retrospective Study.

Biomedicines·2026
Same author

Parameters That May Predict NAC Effectiveness in Hormone-Positive Breast Cancer According to CPS Score.

Cancer management and research·2026
Same author

Distinguishing adrenal metastases from benign lesions in NSCLC: the value of clinical and radiological parameters.

BMC cancer·2026
Same author

Prognostic Impact of the Gustave Roussy Immune Score on Cancer-Specific Survival and Treatment Completion in Patients with Bladder Cancer.

Diagnostics (Basel, Switzerland)·2026

Related Experiment Video

Updated: Jun 25, 2025

Author Spotlight: Exploring the Role of Inflammation in the Co-occurrence of Primary Sjogren's Syndrome and Lung Adenocarcinoma
10:21

Author Spotlight: Exploring the Role of Inflammation in the Co-occurrence of Primary Sjogren's Syndrome and Lung Adenocarcinoma

Published on: September 20, 2024

419

Inflammatory parameters in NSCLC with driver mutation.

Mehmet Emin Buyukbayram1, Zekeriya Hannarici2, Ali Yilmaz3

  • 1Department of Medical Oncology, Atatürk University Faculty of Medicine, Erzurum, 25100, Turkey.

Lung Cancer Management
|May 31, 2024
PubMed
Summary

Peripheral inflammatory markers, like neutrophil-lymphocyte ratio and systemic immune-inflammation index, may predict survival in non-small cell lung cancer (NSCLC) patients with driver mutations.

Keywords:
driver mutationinflammatory markersnon-small-cell lung cancersurvival

More Related Videos

Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer
07:59

Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer

Published on: September 8, 2023

1.1K
Next Generation Sequencing for the Detection of Actionable Mutations in Solid and Liquid Tumors
11:15

Next Generation Sequencing for the Detection of Actionable Mutations in Solid and Liquid Tumors

Published on: September 20, 2016

24.3K

Related Experiment Videos

Last Updated: Jun 25, 2025

Author Spotlight: Exploring the Role of Inflammation in the Co-occurrence of Primary Sjogren's Syndrome and Lung Adenocarcinoma
10:21

Author Spotlight: Exploring the Role of Inflammation in the Co-occurrence of Primary Sjogren's Syndrome and Lung Adenocarcinoma

Published on: September 20, 2024

419
Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer
07:59

Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer

Published on: September 8, 2023

1.1K
Next Generation Sequencing for the Detection of Actionable Mutations in Solid and Liquid Tumors
11:15

Next Generation Sequencing for the Detection of Actionable Mutations in Solid and Liquid Tumors

Published on: September 20, 2016

24.3K

Area of Science:

  • Oncology
  • Immunology

Background:

  • The tumor microenvironment in non-small cell lung cancer (NSCLC) with driver mutations (e.g., EGFR, ALK, ROS) exhibits reduced inflammation.
  • Understanding factors influencing survival in this specific NSCLC subgroup is crucial.

Purpose of the Study:

  • To investigate the association between clinical and inflammatory markers and survival outcomes in NSCLC patients with driver mutations.
  • To determine if peripheral inflammatory parameters can predict progression-free survival (PFS) and overall survival (OS).

Main Methods:

  • Retrospective analysis of 38 NSCLC patients with driver mutations.
  • Kaplan-Meier curves were used to analyze the relationship between clinical/inflammatory markers and PFS/OS.

Main Results:

  • Patients under 65 years old had significantly longer PFS and OS.
  • A low neutrophil-lymphocyte ratio (NLR), low systemic immune-inflammation index (SII), and high lymphocyte count were associated with significantly longer PFS and OS (p < 0.05).

Conclusions:

  • Peripheral inflammatory markers, including NLR, SII, and lymphocyte count, may serve as prognostic indicators for survival in NSCLC patients with driver mutations.
  • These findings suggest that systemic inflammation, rather than solely tumor biology, could influence outcomes in this patient population.